Analysis Of Income And Expense [Abstract]

Innate Pharma - Filing #2821023

Concept	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue from sale of goods	—	—	678,000 EUR	—	—	—	— EUR
Revenue	—	—	70 451 EUR	—	—	—	85 814 EUR
Material income and expense [abstract]
Research and development expense	—	—	58 613 EUR	—	—	—	78 844 EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	—	31 246 EUR	—	—	—	25 803 EUR
Operating expense	—	—	89 859 EUR	—	—	—	104 647 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	805,000 EUR	1 027 EUR	222,000 EUR	—	5,000 EUR	—	5,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	805,000 EUR	827,000 EUR	63 962 EUR	63 984 EUR	627,000 EUR	20 759 EUR	20 132 EUR